Real-world data on home high-flow nasal cannula oxygen therapy in end-stage respiratory disease
Monaldi Archives for Chest Disease · 2025
DOI: 10.4081/monaldi.2025.3269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Monaldi Archives for Chest Disease, 2025. Verfasst von Pedro Magalhães Ferreira und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, University Hospital Center of São João, Porto. Hauptthemen laut MEDLINE: Oxygen Inhalation Therapy, Respiratory Insufficiency, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
High-flow nasal oxygen therapy (HFNOT) is a cornerstone treatment modality in severe acute hypoxemic respiratory failure, with benefits in improving oxygen deficit while normalizing breathing rate and having an effect on airway humidification. These physiological effects indicate a potential benefit in end-stage chronic respiratory failure. We aimed to assess the clinical impact of home HFNOT in reducing both exacerbation rates and overall disease burden in end-stage chronic respiratory disease. We designed a retrospective study including patients followed in the pulmonology department of a tertiary center who started home HFNOT until June 2023. Pre- and post-home HFNOT exacerbations and hospital admissions were registered, and each patient served as their own control for the statistical analysis. In total, 36 patients were included in the study: 24 patients (66.7%) with interstitial lung disease and 12 (33.3%) with obstructive lung disease. Overall, the median titrated fraction of inspired oxygen was significantly lower in obstructive patients; no significant differences were found between groups regarding titrated airflow. Obstructive patients had a significantly higher number of pre-treatment exacerbations and hospital stays. Both clinical subgroups presented less median overall post-treatment exacerbations and hospital admissions vs. pre-treatment start. Although mortality was high, home treatment was well tolerated by most patients, with only one patient interrupting high-flow therapy due to intolerance. Home HFNOT proved to be an overall feasible treatment strategy for patients with end-stage respiratory disease. Obstructive lung disease patients benefited the most from the treatment, possibly due to hypercapnia correction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonology Department, University Hospital Center of São João, Porto.
- Pulmonology Department, University Hospital Center of São João, Porto; Sleep and Non-Invasive Ventilation Unit, University Hospital Center of São João, Porto; Faculty of Medicine, University of Porto.
ORCID-Profile: Pedro Magalhães Ferreira, Mariana Ribeiro, Miguel Gonçalves, Carla Damas
Zitieren
APA
Magalhães Ferreira, P., Ribeiro, M., Gonçalves, M., & Damas, C. (2025). Real-world data on home high-flow nasal cannula oxygen therapy in end-stage respiratory disease. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2025.3269
Vancouver
Magalhães Ferreira P, Ribeiro M, Gonçalves M, Damas C. Real-world data on home high-flow nasal cannula oxygen therapy in end-stage respiratory disease. Monaldi Archives for Chest Disease. 2025. doi:10.4081/monaldi.2025.3269
BibTeX
@article{MagalhesFerreira2025,
author = {Magalhães Ferreira, Pedro and Ribeiro, Mariana and Gonçalves, Miguel and Damas, Carla},
title = {Real-world data on home high-flow nasal cannula oxygen therapy in end-stage respiratory disease},
journal = {Monaldi Archives for Chest Disease},
year = {2025},
doi = {10.4081/monaldi.2025.3269}
}
EUVIMED